Insight Molecular Diagnostics (IMDX) Common Equity (2015 - 2026)

Insight Molecular Diagnostics has disclosed Common Equity across 12 years of filings, most recently posting -$10.7 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$10.7 million, down 204.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.7 million (down 204.63% YoY), and the FY2025 annual result was -$31.5 million, down 156.35% from the prior year.
• Common Equity came in at -$10.7 million for Q1 2026 at Insight Molecular Diagnostics, up from -$31.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $83.2 million in Q2 2022 to a low of -$31.5 million in Q4 2025.
• The 5-year median for Common Equity is $20.5 million (2023), against an average of $22.4 million.
• Across the five-year window, Common Equity slipped 11.82% in 2025 and sank 204.63% in 2026, its largest moves.
• Insight Molecular Diagnostics' Common Equity stood at $34.3 million in 2022, then tumbled by 40.31% to $20.5 million in 2023, then sank by 159.97% to -$12.3 million in 2024, then slumped by 156.35% to -$31.5 million in 2025, then soared by 66.02% to -$10.7 million in 2026.
• The last three Common Equity figures came in at -$10.7 million (Q1 2026), -$31.5 million (Q4 2025), and -$9.2 million (Q3 2025), per Business Quant data.